Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erenumab - Amgen/Novartis

Next Previous
Drug Profile

Erenumab - Amgen/Novartis

Alternative Names: Aimovig; AMG-334; Erenumab-aooe

Latest Information Update: 29 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Indiana University; Novartis; Rigshospitalet
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Phase II Headache; Rosacea; Temporomandibular joint dysfunction syndrome; Trigeminal neuralgia
  • Discontinued Hot flashes

Most Recent Events

  • 07 Jan 2026 Amgen completes the phase-III OASIS(CM) trial in Migraine (In adolescents, In children, Prevention) in USA, Belgium, Canada, Colombia, Finland, Germany, Hungary, Italy, Japan, Poland, Puerto Rico, Russia, United Kingdom (SC) (NCT03832998)
  • 19 Jan 2024 Indiana University in collaboration with Novartis Pharmaceuticals completes a phase II trial in Temporomandibular joint dysfunction syndrome (In adults) in USA (SC) (NCT04884763)
  • 28 Feb 2023 Amgen has patent protection for erenumab in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top